Abel Hall LLC’s Pulmonx LUNG Stock Holding History

Abel Hall LLC’s Portfolio LUNG Stock Details LUNG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-10,654	Closed	-$23.5K	–	908
2025 Q4	$23.5K	Buy	+10,654	New	+$20K	0.01%	695

Other funds holding LUNG

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ECM

ExodusPoint Capital Management New York $15.5B AUM 38.81% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Abel Hall LLC's LUNG Position: Q1 2026 in Review

Abel Hall LLC sold out of Pulmonx (LUNG) in Q1 2026, closing a stake of 10,654 shares — an estimated $23.5K sold.

Abel Hall LLC first reported a position in LUNG in Q4 2025 and held it in 1 quarter. The position peaked at $23.5K in Q4 2025. 114 funds tracked by Wall St. Rank hold LUNG as of Q1 2026.

Abel Hall LLC reported no remaining Pulmonx position as of Q1 2026 after selling out during the quarter.
Abel Hall LLC sold 10,654 Pulmonx shares in Q1 2026, an estimated $23.5K.
Abel Hall LLC first reported a position in Pulmonx in Q4 2025 and held it in 1 quarter.
Abel Hall LLC's Pulmonx position peaked at $23.5K in Q4 2025.
114 funds tracked by Wall St. Rank held Pulmonx as of Q1 2026.

Based on Abel Hall LLC's 13F filing for Q1 2026, filed 28 Apr 2026.